Long-Term Debt: Cullinan Therapeutics Inc (CGEM)

Brandmark of Cullinan Corp (CGEM)

The current market value shown on this chart helps assess the stability of Cullinan Therapeutics (CGEM), whose success is based on trials of the CLN-619 drug. Cullinan Therapeutics (CGEM) is implementing AI-driven design to accelerate the selection of global molecules. Platform development relies on early test results, and the debt load ratio stands at 0.00. Despite intensive expenditures, the current liquidity reserve remains within safe limits.

CGEM (Cullinan Therapeutics Inc) Company Long-Term Debt history from 07/04/2022 to 10/31/2026

Cullinan Therapeutics Inc - analytical breakdowns and key metrics (CGEM)

- current quotes and average value forecast:
Stock Quotes cullinanoncology.com|CGEM - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Cullinan Therapeutics|CGEM - Total Company Value
- book capitalization data:
Net Assets per Single Share Cullinan Therapeutics|CGEM - Company Book Value|Market-to-Book Ratio cullinanoncology.com|CGEM - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Ratio Cullinan Therapeutics|CGEM - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Cullinan Corp|CGEM - Company Total Debt|Debt to Net Assets Ratio Cullinan Therapeutics|CGEM - Company Long-Term Liabilities|Amount of Current Liabilities Cullinan Therapeutics|Quick Ratio cullinanoncology.com
- net income and valuation multiples indicators:
CGEM - Company Net Income
Fundamental company valuation:cullinanoncology.com
Core merchandise of Cullinan Therapeutics, Inc.

For Cullinan Therapeutics (CGEM), which is developing a targeted tumor therapy platform, this indicator determines the volume of borrowed funds with a maturity of more than one year. The metric measures the business's fundamental dependence on creditors, allowing for an assessment of default risk and the issuer's financial autonomy. By analyzing the company's long-term debt structure, an investor can see the balance between borrowed capital and operational stability. Minimal debt combined with partnerships with pharma behemoths confirms the company's ability to fund development through external payments.

Competitor analysis for Cullinan Therapeutics

GMAB - Company Long-Term Liabilities|EXEL - Company Long-Term Debt|Long-Term Debt Nuvalent Inc|Kymera Therapeutics Inc (KYMR) - Company Long-Term Debt|IDYA (IDEAYA Corp) - Company Long-Term Debt|Company Long-Term Debt Enliven Therapeutics|Long-Term Debt oricpharma.com ORIC|Company Long-Term Debts RLAY|Nurix Therapeutics Inc (NRIX) - Long-Term Indebtedness|Tyra Bio - Company Long-Term Liabilities|Verastem Corp (VSTM) - Long-Term Debt|GLUE: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings IMRX (immuneering.com)|CCCC (C4 Therapeutics) - Company Long-Term Liabilities|BDTX: Amount of Long-Term Liabilities|RPTX (Repare Rx) - Company Long-Term Debts|Company Long-Term Debts PMV Pharmaceuticals, Inc|Company Long-Term Debt Karyopharm Therapeutics (KPTI)|PPCB (propanc.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts BGMS (Bio Green Med Solution)|Long-Term Indebtedness Aadi Bioscience Inc|Aileron - Company Long-Term Debts|Long-Term Debt Blueprint Medicines|GLYC (glycomimetics.com) - Company Long-Term Liabilities|SWTX: Amount of Long-Term Liabilities